Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Risankizumab in Moderate to Severe Atopic Dermatitis
2021-002203-34Phase 2
- Sponsor
- AbbVie Inc.
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Risankizumab with Placebo (2 arms). Primary endpoint: EASI 75 Response.
02
Drugs
risankizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-002203-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002203-34.